News Release Details

IDEAYA Biosciences to Present at Upcoming Investor Conferences

October 25, 2019 at 6:00 AM EDT

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that the company is scheduled to present in the following investor conferences:

  • Stifel 2019 Healthcare Conference in New York City, NY. The company is scheduled to present on Wednesday, November 20th at 3:35 pm ET (12:35 pm PST)
  • Jefferies 2019 London Healthcare Conference in London, United Kingdom. The company is scheduled to present on Thursday, November 21st at 7:20am GMT+1 (11:20 pm PST)

About IDEAYA Biosciences

IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing.  IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on August 12, 2019 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Chief Financial Officer
pstone@ideayabio.com

Udeaya_image